Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 22 (Oct 12, 2018)

The Inquiry Committee has reinstated the pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 13, 2015. Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To strictly adhere to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of at least 3 years;

  2. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in his care;

  3. To not work alone in a pharmacy, and to have another pharmacist in good standing supervising him at all times;

  4. To not handle, physically prepare, or dispense prescriptions for opioid medications at any time;

  5. To not have any access whatsoever, on or off duty, to the narcotic safe in any pharmacy;

  6. To not be involved in any way with ordering narcotic medications, except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics;

  7. To inform all managers and employers with whom he gains employment of his medical condition and the limits and conditions on his registration pursuant to the Agreement;

  8. To ensure that all managers and employers with whom he gains employment submits a written statement to the College declaring their awareness of his medical condition and the Agreement, and how they will accommodate and supervise him working in the pharmacy;
     
  9. To inform the College in via e-mail of his places of employment as a pharmacist and report any changes to the location of his employment within 48 hours of such change; and

  10. To be restricted from acting in the following roles in his practice:

    1. Be a manager of a pharmacy;
    2. Be an owner (direct or indirect) of a pharmacy; and
    3. Act as a preceptor.

     


August 13, 2015
(October 12, 2018 – Registration Reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist effective August 13, 2015. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


February 13, 2015
(AUGUST 13, 2015 - Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 5, 2014. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Routine and random medical monitoring;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. Registrant will not be involved in the dispensing, ordering, contact, destruction, counting or otherwise handling of opiate medications and other medications with abusive potential;

  8. Being restricted from the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor.

     

  9. Notifying the College of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

     

The agreement will remain in place for a minimum of three years of continuous pharmacy practice. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public. 


August 5, 2014
(February 13, 2015 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist effective August 5, 2014. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 39 (Sep 24, 2018)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend her registration as a pharmacist effective September 24, 2018.  The agreement remains in effect until further notice.  The Inquiry Committee considers the agreement necessary to protect the public.  The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacist Registrant 38 (Sep 5, 2018)

The Inquiry Committee has reached an agreement with the pharmacist registrant to amend one of the terms in his Agreement of August 2, 2018. While the pharmacist registrant is still limited to working in a pharmacy for no more than four hours a day, he can now work up to eight hours up to two days per week, if necessary to ensure sufficient pharmacist staff levels.


August 2, 2018
(September 5, 2018 - Limits and Conditions Updated)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(i) of the Health Professions Act, has reached an agreement with the pharmacist registrant to place limits and conditions on his pharmacy practice, pending further disposition of the Inquiry Committee. The pharmacist registrant will be limited to working in a pharmacy for no more than four hours a day and must work with another pharmacy staff member at all times. The Inquiry Committee considers this agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

Pharmacist Registrant 26 (Sep 3, 2018)

The Inquiry Committee, pursuant to Section 36(1) of the Health Professions Act, has reached an agreement with the pharmacist registrant to further amend one of the terms in his Agreement of June 4, 2017. The pharmacist registrant can now work in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a monthly basis.


January 17, 2018
(September 3, 2018 - Limits and Conditions Updated)

The Inquiry Committee, pursuant to Section 36(1) of the Health Professions Act, has reached an agreement with the pharmacist registrant to amend one of the terms in his Agreement of June 4, 2017. The pharmacist registrant can now work in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a biweekly basis.


June 4, 2017
(January 17, 2018 - Limits and conditions updated)

The Inquiry Committee, pursuant to Section 36(1) of the Health Professions Act, has reached a new revised Agreement with the pharmacist registrant whereby the registrant consented to undertakings that include, but are not limited to:

  1. Complying with all terms of the registrant’s monitoring program for a minimum of three additional years;

  2. Continuing counselling for one year from the date after he had returned to work;

  3. Informing all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to the Agreement;

  4. Ensuring that all managers and employers with whom registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise registrant working in pharmacy;

  5. Working in a pharmacy where narcotic/controlled substances and Z-group drugs are counted and reconciled on a weekly basis;

  6. Working a maximum number of hours and shifts per week for the first three months after signing the Agreement;

  7. Informing his pharmacy manager of all wastages and breakages of narcotic, controlled, opioid and sedative drugs that he has to dispose of or deal with;

  8. Not conducting drug counts and/or conduct medication reconciliation for any narcotic/controlled substances or Z-group drugs;

  9. The registrant will be restricted from acting in the following roles:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  10. The registrant will notify the College regarding any of the following changes:

    1. changes in places of employment as a pharmacist;
    2. changes in residential address and phone number; and
    3. changes in medical provider;

     

The Agreement will remain in place for a minimum of four years or until such time as the registrant’s physician states otherwise. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.


January 3, 2017
(June 4, 2017 – Limits and conditions updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended indefinitely on May 16, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with the pharmacist registrant whereby the registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. That the registrant will comply with all terms of registrant’s monitoring program with the company currently involved in registrant’s care and remain on this program for a minimum of three (3) years from the day registrant returns to active employment as a pharmacist;

  2. That registrant will continue counselling for one (1) year after registrant returns to work;

  3. That registrant will inform all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to this agreement;

  4. That registrant will ensure that all managers and employers with whom registrant gains employment submit a written statement to the College within 48 hours of securing employment, declaring their awareness of registrant’s medical condition and the agreement, how they will accommodate and supervise registrant working in the pharmacy, and that they will submit a weekly narcotic count for a minimum of three (3) months to the College or advise the College if any narcotic count concerns arise;

  5. That after returning to work in a pharmacy setting, registrant will provide work sign-in sheets on a monthly basis;

  6. That registrant will not work alone after returning to work in a pharmacy setting and that there must be overlapping shifts of at least one registrant during registrant’s work shift for a minimum of the first six (6) months that registrant returns to work;

  7. That after returning to work in a pharmacy setting, registrant will not be allowed to dispense narcotics;

  8. That after returning to work in a pharmacy setting, registrant will not handle or physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  9. That after returning to work in a pharmacy setting, for the first six (6) months, registrant will not be allowed to dispense Controlled Substances ie. Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs (which are not considered Controlled Substances);

  10. That after returning to work in a pharmacy setting, registrant will not be allowed to do narcotic or controlled substances or Z-Group drug counts;

  11. That after returning to work in a pharmacy setting, registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs, including but not limited to Benzodiazepine, Dextroamphetamine and testosterone products and any Z-Group drugs;

  12. That registrant will not have access to the narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  13. That registrant will not be involved in any way with ordering supplies of narcotic medications;

  14. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  15. That registrant will be restricted from acting in the following roles in registrant’s practice: 

    1. all changes in places of employment as a pharmacist;
    2. all changes in residential address and phone number; and
    3. all changes in medical provider;

The agreement will remain in place for a minimum of five years from the date of execution of the agreement. The registrant will be assessed by the treating physician after six (6) months upon return to active employment to determine whether or not any of the above limits or conditions should be removed. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


May 16, 2016
(January 3, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 16, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Pharmacy Technician Registrant 3 (Sep 1, 2018)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacy technician registrant to suspend her registration as a pharmacy technician for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The registered pharmacy technician registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Zhao, David (Aug 19, 2018)

Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with David Zhao (the “Registrant”) to suspend his registration as a pharmacist for 365 consecutive days commencing September 4, 2018.

The Registrant acknowledged that between March 6, 2016 and January 18, 2017, while engaged in the practice of pharmacy as a pharmacist and pharmacy manager, he processed 526 false prescription claims to his insurance provider for reimbursement. The Registrant acknowledged that by processing false prescriptions, he also falsified pharmacy drug and inventory records.

The Registrant also acknowledged that while he was pharmacy manager, he was responsible for multiple practice deficiencies including processing prescriptions for his family members to artificially increase the pharmacy’s prescription count, engaging in a conflict of interest, and backdating prescriptions (meaning that dispensing records for these prescriptions were created on dates later than the dates on which the drugs in question were actually dispensed).

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • Meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned; and
  • Complete an ethics course at his own expense.

The Registrant will also be limited from being a manager, direct owner and/or indirect owner of a pharmacy for a period of three years from the date his suspension ends (commencing September 4, 2019).

The Inquiry Committee considers this agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct. 

Phalore, Jagbir (Aug 3, 2018)

The Inquiry Committee has reviewed information that indicates Mr. Phalore’s practice is now meeting practice standards. Therefore, after reviewing and reconsidering this case, the Inquiry Committee determined that the current limits and conditions on Mr. Phalore’s practice are no longer necessary.

Limits and conditions on Mr. Phalore’s practice have now been removed.


November 29, 2016
(August 3, 2018 – Limits and conditions removed)

Pursuant to s. 35(4) of the Health Professions Act, the Inquiry Committee has determined that the limits and conditions imposed on the practice of pharmacy by Mr. Jagbir Phalore on May 16, 2016 are no longer necessary.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with Mr. Phalore, effective November 29, 2016, where he undertaken to always follow certain steps in his pharmacy practice, and to disclose these undertakings to employers and potential employers. He will also be restricted from acting the following roles in his practice:

  1. Be an owner or manager of a pharmacy;
  2. Be a director of a corporation that owns a pharmacy; and
  3. Act as a preceptor.

After two years from November 29, 2016, Mr. Phalore may request that the Inquiry Committee remove the above limits and conditions, subject to a further review of the case by the Inquiry Committee.


May 16, 2016
(November 29, 2016 - Limits and conditions updated) 

The Inquiry Committee, pursuant to Section 35(1) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Jagbir Phalore, effective immediately, pending a Practice Audit of his pharmacy practice. Until further notice, Mr. Phalore has the following limits and conditions on his practice:

  1. At all times, he must work under the direct supervision of a BC licensed pharmacist in good standing, similar to a student/preceptor situation; 

  2. He will be restricted from acting in the following roles in his practice: :

    1. Be an owner or manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor.

     

  3. Prior to the commencement of new employment at any pharmacy, he will inform every manager and employer of the pharmacy in which he gains employment of the limits and conditions on his license pursuant to this order, and will ensure that the pharmacy manager and employer submits a written statement to the College declaring their awareness of the limits and conditions and how the limits and conditions will be accommodated in the pharmacy.

The Inquiry Committee considered this action necessary to protect the public, due to its concerns regarding the registrant’s ability to practice safely and to comply with legislative requirements and practice standards in a hospital and/or community pharmacy setting.

Pharmacy Technician Registrant 2 (Jul 27, 2018)

The Inquiry Committee, pursuant to Section 32.2 of the Health Professions Act, has reached an agreement with pharmacy technician registrant to suspend her registration as a pharmacy technician for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Zanotto , Aaron Ariel Glaser (Jul 20, 2018)

Pursuant to section 35(1)(b) of the Health Professions Act, effective July 20, 2018, the Inquiry Committee has directed an extraordinary suspension of the registration of registrant Aaron Ariel Glaser Zanotto pending completion of an investigation. The registrant will not be able to practice pharmacy in the province of British Columbia while his registration is suspended. The Inquiry Committee considered the extraordinary suspension necessary to protect the public.

While practicing as a pharmacist, the registrant allegedly made online postings, the contents of which may be regarded as reflecting harm and a risk to the public.

Note: Suspensions ordered by the Inquiry Committee under section 35(1)(b) of the Health Professions Act are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Pharmacist Registrant 34 (Jul 4, 2018)

The Inquiry Committee has reinstated Pharmacist Registrant’s registration which had previously be suspended for an indefinite period on February 10, 2018.  Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings.  The undertakings include, but are not limited to:

  1. The Registrant will comply with any and all recommendations and treatment prescribed or directed by his physician; and
  2. The Registrant will follow a regular monitoring program for his medical condition for a two year period. 

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4) and (6) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public. 


Feb 10, 2018
(July 4, 2018 - Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pages